Abstract: The present invention provides formulations and methods useful in the control of ectoparasites on a domestic animal, using a formulation comprising Indoxacarb and a veterinarily acceptable carrier that is applied topically to 10% or less of the total surface area of a domestic animal. Other embodiments include these formulations also including one or more additional pesticides such as fipronil.

Abstract: Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (COX-2 inhibitor). Said methods comprise basing COX-2 inhibitor dose on each patient's pharmacokinetic response to said COX-2 inhibitor.

Abstract: This invention provides methods and compositions for treating or preventing migraine headache and/or symptoms thereof in a subject. The method comprises administering to the subject in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a nutritional and medicinal oral composition for veterinary use, comprising a core of an extruded product of complete feed coated with at least one layer of fatty material, said layer of fatty material comprising at least one active substance in a microparticulate form selected from benazepril, benazeprilat and a pharmaceutically acceptable salt thereof, said active substance being (i) pre-conditioned in the form of an oily suspension of said active substance or (ii) pre-conditioned in the form of waxy granules of said active substance.

Abstract: Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR7, including those of Formula II: and pharmaceutically acceptable salts thereof, useful in treating HIV infections.

Abstract: The present invention relates to a multilayer tablet formulation comprising a combination of quetiapine or a pharmaceutically acceptable salt thereof and escitalopram or a pharmaceutically acceptable salt thereof.

Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating a level and/or activity of a hormone and methods and uses for treating a gender-biased immune disorder using such compositions.

Abstract: This invention is for formulations of analogs of the non-toxic and inert Vitamin D3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, Vitamin D deficiency, autoimmune disease such as Multiple Sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert Vitamin D3 and the non-toxic and mostly inert Vitamin D3 pre-hormone.

Abstract: The present invention provides a method for inducing apoptosis in selected cells by aggravating ER-stress. The aggravation of ER-stress is achieved in a specific manner by inhibiting SERCA (sarcoplasmic/endoplasmic reticulum calcium ATPase), leading to elevated level of cytoplasmic calcium concentration, yet without inhibiting the activity of COX-2 (cyclooxygenase-2) or triggering the release of histamine. Induction of apoptosis may be enhanced by first inducing or further aggravating ER-stress through inhibition of proteasome or proteases. Also provided are compounds and compositions useful as ER-stress aggravating agents, methods for screening, selecting, identifying and designing the same and methods for treating diseased conditions by inducing apoptosis through specific and selective aggravation of ER-stress.

Abstract: The present invention relates to a once daily tablet comprising doxycycline at sub-antibiotic dose and one or more pharmaceutically acceptable excipients, wherein the tablet exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline tablet with or without food. A process of preparing the tablet is also provided.

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for diagnosing and treating MYC-driven tumors. In one embodiment, a method for treating a cancer associated with MYC in a patient comprises the step of administering a glutamine metabolism inhibitor to the patient. In specific embodiments, the cancer associated with MYC is medulloblastoma, glioblastoma or a primitive neuroectodermal tumor.

Abstract: Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel until dosage forms of VB-201 and methods utilizing same are also disclosed.

Abstract: The present invention provides a method of treating cancer with a proteasome inhibitor. The invention also provides a method of treating a patient with cancer based on elevated expression levels of NF?B, as measured by a H-score of the patients tumor sample using a NF?B p65 IHC assay. The invention also provides a method of determining whether to treat a patient with a proteasome inhibitor based on the level of NF?B p65 in the patient's tumor sample.

Abstract: Described herein are dosing regimens and kits for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).

Abstract: The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition comprising a prebiotic, optionally in combination with effective amount of a probiotic microbe or microbes.

Abstract: It is an object of the invention to discover a substance that effectively increases the production of adrenomedullin, as well as to provide an adrenomedullin production-enhancing agent utilizing this substance. The adrenomedullin production-enhancing agent is characterized by inclusion of a ginsenoside, a sanshool, and/or a shogaol as active ingredients.

Abstract: A composition for inducing erythropoietin (EPO)-mediated haemoglobin (Hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (I), wherein R is a glycosyl group; and a pharmaceutical acceptable carrier.

Abstract: Agents and devices for affecting nerve function are described. In some variations, a combination of agents, e.g., a cardiac glycoside, an ACE inhibitor, and an NSAID are delivered to affect nerve function. The agent may be delivered locally in a site-specific manner to a targeted nerve or portion of a nerve. For example, the agent may be delivered locally to the renal nerves to impair their function and treat hypertension. One variation of a delivery device includes one or more needle housings supported by a balloon. A delivery needle is slidably disposed within a needle lumen of each needle housing.

Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.

Abstract: The present invention relates to modified oligonucleotides of 5-50 nucleotide residues, wherein at least 25% of the nucleotides are independently modified at the 2? position to comprise the structure of formula (I), wherein base is a purine or pyrimidine moiety; and R1, R2, R3, R4, p and q are as defined in the description. The modified oligonucleotides comprising said structures are useful as medicaments for enhancement of drug uptake in oligonucleotide based therapy in humans and animals.

Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.

Abstract: A first object of the invention is galactosaminogalactan comprising ?1-4 linked galactose, ?1-4 linked N-acetylgalactosamine, and optionally ?1-4 linked galactosamine, for use in the treatment of at least one inflammatory disease. Another object of the invention is a pharmaceutical composition comprising a galactosaminogalactan comprising ?1-4 linked galactose, ?1-4 linked N-acetylgalactosamine, and optionally ?1-4 linked galactosamine, as defined herein, and optionally a pharmaceutically acceptable carrier. Another object of the invention is a pharmaceutical composition according to the invention, for use in the treatment of at least one inflammatory disease. Another object of the invention is an inhibitor of IL-1RA for use in the treatment of human fungal diseases. Another object of the invention is a pharmaceutical composition comprising an inhibitor of IL-1RA, and optionally a pharmaceutically acceptable carrier.

Abstract: The present invention addresses the problem of providing an agent for lifestyle-related diseases, an oral composition, and a high-fat food product that can be conveniently, safely, and continuously consumed on a daily basis. This problem is solved by an agent for lifestyle-related diseases that contains a specific branched ?-glucan having the characteristics described in the present invention, an oral composition comprising the agent, and a high-fat food product comprising the same.

Abstract: It is disclosed a method for treating hepatitis B virus infection or hepatitis B virus/hepatits delta virus co-infection, the method comprising administering to a subject in need of such treatment a first pharmaceutically acceptable agent that comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent that comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor.

Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. Sodium nitrite is a naturally occurring compound that is commonly used as a preservative in meats. Due to its vasodilative properties and involvement in the nitric oxide pathway, drug development companies and researchers are also investigating sodium nitrite as a therapeutic agent.

Abstract: The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production including, but not limited to, gout, Lesch-Nyhan syndrome, hemochromatosis, Alzheimer's, amyotropic lateral sclerosis, arthritis, atherosclerosis, cancer, cataracts, chronic obstructive pulmonary disease, diabetes, cellulitis, coronary artery disease, heart failure, hypertension, inflammatory bowel disease, macular degeneration, multiple sclerosis, Parkinson's, Reynaud's phenomenon, reperfusion injury, pancreatic impairment, skin infections, Hepatitis C, methicillin-resistant Staphylococcus aureus and infection.

Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.

Abstract: Compositions and methods of modulating an immune response by controlling expression levels of microRNAs in dendritic cells are disclosed. In particular, the invention relates to modified dendritic cells and methods of using such dendritic cells in cellular therapy for treating various immune conditions and diseases, including transplant rejection, inflammatory disorders, autoimmune diseases, allergies, infectious diseases, immunodeficiency, and cancer.

Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.

Abstract: The present invention provides human CD34-negative progenitor cells for the use in protecting the vascular endothelium from immunologically mediated cytotoxic reactions of a subject at risk of, or afflicted with, vascular inflammatory disease. Also provided are a method for producing the human CD34-negative progenitor cells and a method for determining the ability of CD34-negative progenitor cells to protect the vascular endothelium from immunologically mediated cytotoxic reactions.

Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

Abstract: Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterised by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are abnormally activated.

Abstract: The invention generally relates to postnatal dental stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal dental pulp stem cells, use of the cells to generate dentin, and differentiation of the cells. In another aspect, the invention relates to human postnatal deciduous dental pulp multipotent stem cells, use of the cells to generate dentin, and differentiation of the cells.

Abstract: A method of treatment for pulpitis and/or enhancement for dentinogenesis, includes using dental materials that include at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein as an active ingredient. The dental materials can also contain a carrier having biocompatibility, and can contain at least one cell type among pulp cells, pulp stem cells, pulp progenitor cells, odontoblasts or cells that can differentiate into odontoblasts.

Abstract: A traditional Chinese medicine complex composite for significantly improving high density lipoprotein (HDL) concentration in serum, includes: a tablet which includes 30%-50% hawthorn from north China, 10%-30% radix aucklandiae, 10%-30% radix glehniae and 10%-30% ligusticum wallichii; and a powder which includes 40%-60% beef, 15%-35% bovine sinew, 15%-35% pigskin and 0.5%-2.5% Chinese-date. The tablet is prepared by decocting and boiling the raw material medicine with water, and the powder is prepared by catalytic hydrolysis with an enzyme, the pigskin in the powder can be replaced with bovine skin or donkey skin, and the bovine sinew can be replaced with bovine tendon.

Abstract: A portable apparatus for collection and processing of human biological material containing adipose, such as extracted during a lipoplasty procedure, is useful for multi-step processing to prepare a concentrated product (e.g., stromal vascular fraction) or a fat graft composition. The apparatus has a container with an internal containment volume with a tissue retention volume and a filtrate volume separated by a filter and with a tapered portion to a collection volume for collecting concentrate product. The apparatus has fluid suction features including a suction port and a conduit providing fluid communication from the suction port to a location within the filtrate volume within a tapered portion of the internal containment volume, and optionally including a second suction port and a second conduit to a different location in the filtrate volume with the second conduit being configured to permit elevation adjustment within the filtrate volume.

Abstract: [Problem] To provide a method for producing human corneal epithelial sheet, wherein the human corneal epithelial-derived cells obtained by culturing human corneal epithelial cells are cultured on an amnion substrate. [Solution] A method for culturing human corneal epithelial cells using mesenchymal stem cells as the feeder cells; and a method for culturing human corneal epithelial cells using a medium containing a ROCK inhibitor, a phosphodiesterase inhibitor, a MAP kinase inhibitor and a TGF-? receptor inhibitor in various combinations.

Abstract: Embodiments of the present invention may include a method for improving handling characteristics of an amnion tissue. The method may include providing the amnion tissue from a human donor. Furthermore, the method may include exposing the amnion tissue to supercritical carbon dioxide to form an exposed amnion tissue. The exposed amnion tissue may have a higher ultimate tensile strength and elastic modulus than the amnion tissue before the exposure.

Abstract: The present invention provides compositions and formulations of micronized Wharton's jelly having a controlled viscosity such that when delivered to the injured region of a subject, it remains substantially localized with little or no migration out of the injured region for the repair and/or regeneration thereof. Micronized Wharton's Jelly can be suspended in a pharmaceutically acceptable aqueous carrier, such as saline, sterile water, or any suitable buffer, to form a suspension or a gelatinous gel composition, or it can be in the form of a paste, suitable for delivery into the space adjacent the articular surface cartilage injured region of a subject. The micronized Wharton's jelly when employed at sufficient concentrations can be hydrated into a gel or paste and administered topically, or it can be injected into the body through the use of a needle and syringe.

Abstract: The invention relates to bacterial strains having an outstanding ability to produce menaquinone and to applications thereof.

Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.

Abstract: A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

Abstract: The present invention provides a pharmaceutical composition containing a Sceptridium japonicum extract, as an active ingredient, for preventing or treating stroke or degenerative brain diseases. The Sceptridium japonicum extract of the present invention has a protective effect on cranial nerves so as to exhibit a functional effect of preventing or treating stroke or various degenerative brain diseases.

Abstract: Provided herein are cream formulations comprising sandalwood oil, an antioxidant and a phosphate buffer. Also provided are methods of making and using the formulations. Further provided herein is a method of treating a skin disorder in a subject by administering to the subject a therapeutically effective amount of a cream formulation comprising sandalwood oil, an antioxidant and a phosphate buffer, wherein the subject has a skin disorder or is at risk of developing a skin disorder.

Abstract: The invention provides formulations to prevent or treat decreasing platelet cell counts. The formulations essentially consist of peanut skins, papaya leaves, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, selenium, and iron. In some formulations, some vitamins are replaced by fruit or vegetable juice.

Abstract: The present disclosure is drawn to methods for producing natural extracts utilizing fulvic acid solutions as well as the extracts produced utilizing the disclosed methods. The method provides for selecting natural material(s) for extraction and contacting the natural material with a fulvic acid solution. In some embodiments the contacting can occur by pouring, dripping, sprinkling, submersing, or substantially submersing the natural material with the fulvic acid solution.

Abstract: A method for manufacturing water-soluble medical amber causes that original great molecular groups of medical amber crystals are decomposed into hydrophilic extracted liquid plentiful of water and having small molecular groups, which can be directly coated on skin without mixing with water and added with grease or oil. The method original performs disinfecting and sterilizing treatment for natural medical amber crystals; after a polishing and cleaning step, they are placed in a bottle with treatment liquid therein for a predetermined time period so that the mixture in the bottle ferments and decomposes into small pieces which presents as cream-like liquid. Then paddies are added into the bottle. The bottle is retained through several months so that the medical amber crystals ferment quickly to form as a liquid composite. Then the bottle is evaporated several hours so that the liquid composite is distilled out of the bottle.

Abstract: Compositions and methods are provided for treating or preventing a parasitic disease in a subject. Aspects of the methods include administering an ALDH antagonist to a subject that is infected with a parasite or that is at risk for being infected with a parasite. Also provided are reagents, devices and kits thereof that find use in practicing the subject methods.